Bayesian Capital Management’s CareMax, Inc. Class A Common Stock CMAX Stock Holding History

Bayesian Capital Management’s Portfolio CMAX Stock Details CMAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-403	Closed	-$44K	–	1113
2022 Q2	$44K	Buy	+403	New	+$69.1K	0.01%	718

Other funds holding CMAX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bayesian Capital Management's CMAX Position: Q3 2022 in Review

Bayesian Capital Management sold out of CareMax, Inc. Class A Common Stock (CMAX) in Q3 2022, closing a stake of 403 shares — an estimated $44K sold.

Bayesian Capital Management first reported a position in CMAX in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 81 funds tracked by Wall St. Rank hold CMAX as of Q3 2022.

Bayesian Capital Management reported no remaining CareMax, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Bayesian Capital Management sold 403 CareMax, Inc. Class A Common Stock shares in Q3 2022, an estimated $44K.
Bayesian Capital Management first reported a position in CareMax, Inc. Class A Common Stock in Q2 2022 and held it in 1 quarter.
Bayesian Capital Management's CareMax, Inc. Class A Common Stock position peaked at $44K in Q2 2022.
81 funds tracked by Wall St. Rank held CareMax, Inc. Class A Common Stock as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.